BRPI1013927A2 - métodos e composições para o tratamento de lúpus - Google Patents

métodos e composições para o tratamento de lúpus

Info

Publication number: BRPI1013927A2
Authority: BR; Brazil
Prior art keywords: compositions; methods; treating lupus; lupus; treating
Prior art date: 2009-05-13

Application number

BRPI1013927A

Other languages

English (en)

Inventor

Bruce L Roberts

Johanne M Kaplan

William M Siders

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-13

Filing date

2010-05-13

Publication date

2016-04-05

2010-05-13 Application filed by Genzyme Corp filed Critical Genzyme Corp

2016-04-05 Publication of BRPI1013927A2 publication Critical patent/BRPI1013927A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Microbiology (AREA)

BRPI1013927A 2009-05-13 2010-05-13 métodos e composições para o tratamento de lúpus BRPI1013927A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17792409P	2009-05-13	2009-05-13
PCT/US2010/034741 WO2010132683A1 (en)	2009-05-13	2010-05-13	Methods and compositions for treating lupus

Publications (1)

Publication Number	Publication Date
BRPI1013927A2 true BRPI1013927A2 (pt)	2016-04-05

Family

ID=43085330

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1013927A BRPI1013927A2 (pt)	2009-05-13	2010-05-13	métodos e composições para o tratamento de lúpus

Country Status (12)

Country	Link
US (2)	US9617343B2 (pt)
EP (2)	EP3345620B1 (pt)
JP (3)	JP5834004B2 (pt)
KR (1)	KR101800467B1 (pt)
CN (2)	CN102438654A (pt)
AU (2)	AU2010248935B2 (pt)
BR (1)	BRPI1013927A2 (pt)
CA (1)	CA2761885A1 (pt)
IL (1)	IL216146A0 (pt)
MX (1)	MX342907B (pt)
RU (1)	RU2607022C2 (pt)
WO (1)	WO2010132683A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ621170A (en)	2009-05-13	2015-08-28	Genzyme Corp	Anti-human cd52 immunoglobulins
WO2013107413A1 (zh) *	2012-01-19	2013-07-25	中国科学院上海巴斯德研究所	磷酸化途径相关因子在调控调节性t细胞功能中的应用
EP2954071B1 (en) *	2013-02-08	2020-08-12	Allegheny-Singer Research Institute	Cell-bound complement activation products as diagnostic biomarkers for pre-lupus
AR095199A1 (es)	2013-03-15	2015-09-30	Genzyme Corp	Anticuerpos anti-cd52
CA2899835A1 (en)	2013-03-20	2014-09-25	F. Hoffmann-La Roche Ag	Specific detection of rat antibodies in mouse serum
PL3105317T3 (pl)	2014-02-14	2019-02-28	Cellectis	Komórki do immunoterapii zaprojektowane do celowania antygenu obecnego zarówno na komórkach odpornościowych, jak i komórkach patologicznych
CN107249602B (zh) *	2015-02-27	2021-09-28	美商生物细胞基因治疗有限公司	靶向血液恶性肿瘤之嵌合抗原受体（car）、其组合物及使用方法
CN107849112B (zh)	2015-06-25	2022-04-01	美商生物细胞基因治疗有限公司	嵌合抗原受体(car)、组合物及其使用方法
US11173179B2 (en)	2015-06-25	2021-11-16	Icell Gene Therapeutics Llc	Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
JP7114490B2 (ja)	2016-06-24	2022-08-08	アイセル・ジーン・セラピューティクス・エルエルシー	キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
CN118853581A (zh)	2017-06-21	2024-10-29	美商生物细胞基因治疗有限公司	嵌合抗原受体(CARs)、组合物及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9022543D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Antibody production
GB9022547D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Purified immunoglobulin
GB9125768D0 (en)	1991-12-04	1992-02-05	Hale Geoffrey	Therapeutic method
US7119248B1 (en)	1994-04-12	2006-10-10	Miltenyi Biotec Gmbh	Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US7060802B1 (en) *	2000-09-18	2006-06-13	The Trustees Of Columbia University In The City Of New York	Tumor-associated marker
US7465790B2 (en)	2000-10-09	2008-12-16	Isis Innovation, Inc.	Therapeutic antibodies
US20050191632A1 (en) *	2002-11-01	2005-09-01	John Byrd	Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
US7534427B2 (en)	2002-12-31	2009-05-19	Immunomedics, Inc.	Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
KR20060002896A (ko)	2003-03-31	2006-01-09	기린 비루 가부시키가이샤	항 ｃｄ52 항체에 의한 조절성 ｔ 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물
DK1694706T3 (da)	2003-11-01	2012-07-16	Merck Patent Gmbh	Modificeret anti-CD52-antistof
CA2562771C (en)	2004-04-12	2013-04-09	Medimmune, Inc.	Anti-il-9 antibody formulations and uses thereof
CN101443040A (zh) *	2006-03-16	2009-05-27	基因技术股份有限公司	用cd4抗体治疗狼疮的方法
ATE460922T1 (de)	2006-04-07	2010-04-15	Chimeros Inc	Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
DK2012814T3 (da) *	2006-04-12	2013-08-19	Genzyme Corp	Fremgangsmåder til behandling af autoimmunsygdomme
GB0608054D0 (en)	2006-04-24	2006-05-31	Isis Innovation	Production and use of regulatory t cells
CA2653848A1 (en) *	2006-05-31	2007-12-06	Genzyme Corporation	Methods of using anti-thymocyte globulin and related agents
JP2009543579A (ja) *	2006-07-19	2009-12-10	ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア	抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
WO2008140484A2 (en)	2006-11-09	2008-11-20	Xdx, Inc.	Methods for diagnosing and monitoring the status of systemic lupus erythematosus
NZ621170A (en)	2009-05-13	2015-08-28	Genzyme Corp	Anti-human cd52 immunoglobulins
AR095199A1 (es)	2013-03-15	2015-09-30	Genzyme Corp	Anticuerpos anti-cd52

2010
- 2010-05-13 RU RU2011150495A patent/RU2607022C2/ru active
- 2010-05-13 CA CA2761885A patent/CA2761885A1/en not_active Withdrawn
- 2010-05-13 CN CN2010800209534A patent/CN102438654A/zh active Pending
- 2010-05-13 KR KR1020117029688A patent/KR101800467B1/ko active Active
- 2010-05-13 AU AU2010248935A patent/AU2010248935B2/en active Active
- 2010-05-13 JP JP2012511015A patent/JP5834004B2/ja active Active
- 2010-05-13 WO PCT/US2010/034741 patent/WO2010132683A1/en not_active Ceased
- 2010-05-13 CN CN201910644240.8A patent/CN110179989B/zh active Active
- 2010-05-13 MX MX2011012048A patent/MX342907B/es active IP Right Grant
- 2010-05-13 US US13/320,001 patent/US9617343B2/en active Active
- 2010-05-13 EP EP17206028.7A patent/EP3345620B1/en active Active
- 2010-05-13 BR BRPI1013927A patent/BRPI1013927A2/pt not_active Application Discontinuation
- 2010-05-13 EP EP10775545.6A patent/EP2429583A4/en not_active Withdrawn
2011
- 2011-11-03 IL IL216146A patent/IL216146A0/en active IP Right Grant
2014
- 2014-12-11 JP JP2014250861A patent/JP2015052021A/ja not_active Withdrawn
2016
- 2016-10-06 JP JP2016197833A patent/JP2017008106A/ja active Pending
2017
- 2017-03-01 US US15/446,162 patent/US20170369583A1/en not_active Abandoned
- 2017-03-15 AU AU2017201771A patent/AU2017201771A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2010132683A1 (en)	2010-11-18
MX2011012048A (es)	2011-12-12
EP2429583A1 (en)	2012-03-21
CN110179989B (zh)	2022-06-24
AU2017201771A1 (en)	2017-04-06
CN110179989A (zh)	2019-08-30
JP2017008106A (ja)	2017-01-12
EP3345620A1 (en)	2018-07-11
KR101800467B1 (ko)	2017-11-22
EP2429583A4 (en)	2013-10-16
IL216146A0 (en)	2012-01-31
MX342907B (es)	2016-10-17
JP5834004B2 (ja)	2015-12-16
US20170369583A1 (en)	2017-12-28
RU2607022C2 (ru)	2017-01-10
US9617343B2 (en)	2017-04-11
RU2011150495A (ru)	2013-06-20
CA2761885A1 (en)	2010-11-18
US20120070408A1 (en)	2012-03-22
KR20140014392A (ko)	2014-02-06
JP2015052021A (ja)	2015-03-19
EP3345620B1 (en)	2024-08-28
CN102438654A (zh)	2012-05-02
AU2010248935B2 (en)	2016-12-15
JP2012526846A (ja)	2012-11-01
AU2010248935A1 (en)	2011-11-17

Publication	Publication Date	Title
BRPI1013927A2 (pt)	2016-04-05	métodos e composições para o tratamento de lúpus
BR112012004979A2 (pt)	2015-09-08	composições para o tratamento de semente e métodos
BRPI1011325A2 (pt)	2016-03-15	composições e métodos para o tratamento de inflamação
BR112012028514A2 (pt)	2017-11-21	composição para o tratamento da água residual e processo para o tratamento de água residual
BRPI1007972A2 (pt)	2016-09-13	composições de combinação e métodos para o tratamento de câncer
BR112013019732A2 (pt)	2016-10-25	composições e métodos para tratamento de doenças cardiovasculares
IL224390B (en)	2020-02-27	Compositions and methods for targeted thermal modulation
BRPI0919238A2 (pt)	2019-09-24	métodos e composições para o tratamento de câncer
BRPI1012182A2 (pt)	2016-04-05	composições e métodos para tratar isquemia e lesão de isquemia-reperfusão
BR112013008957A2 (pt)	2019-09-24	composições e métodos para tratamento de doenças endócrinas, gastrointestinais ou autoimunes
EP2655334A4 (en)	2014-12-31	COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
PT2512502T (pt)	2018-05-02	Métodos e composições para supressão de tumores
BRPI1008326A2 (pt)	2015-08-25	Composições e métodos para controlar nanatódeos
BRPI1007600A2 (pt)	2019-09-24	composições e métodos para tratamento de doenças cardiovasculares
BRPI0921959A2 (pt)	2017-05-30	métodos e composições para remoção de tatuagem
BRPI0909164A2 (pt)	2016-06-21	método e composições para o tratamento de câncer
FI20096058A0 (fi)	2009-10-13	Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
PT2632452T (pt)	2019-01-10	Compostos e composições para o tratamento do cancro
BRPI1007929A2 (pt)	2015-09-01	"métodos e composições para o tratamento de neovascularização".
BRPI0811930A2 (pt)	2014-11-25	Métodos e composições para a identificação e o tratamento de lúpus
BR112012004080A2 (pt)	2016-03-08	composições farmacêuticas para tratar ibd
BR112012002084A2 (pt)	2016-11-08	composições e métodos para inibir crescimento de pelo
BR112012004699A2 (pt)	2015-09-01	Métodos e composições para lise química direta
BR112012006437A2 (pt)	2016-04-19	composições e métodos para tratamento do diabetes e outros distúrbios
BR112013028890A2 (pt)	2017-01-31	composições e métodos para o tratamento de câncer

Legal Events

Date	Code	Title
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-07-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-04-30	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-12-17	B09B	Patent application refused [chapter 9.2 patent gazette]
2020-03-10	B12B	Appeal against refusal [chapter 12.2 patent gazette]